top of page



KdT Logo (left) HD.png

KdT Ventures is the standard in early-stage biotech investing. We help founders and their companies re-architect the world at a molecular level. 

Notable events:

PathAI secures a $60M Series B from General Atlantic and General Catalyst

Solugen raises another $32M to continue disrupting the chemicals industry

54Gene is capturing the missing diversity in the human genome

"Phil started on the ground floor at StrideBio, helping us compile and evaluate a clinical pipeline that highlighted our technology's key strengths, and he has seen the evolution of these projects as they begin to come to life. His ability to synthesize scientific, commercial, and medical information provides invaluable input to our discussions."


Aravind Asokan, PhD

"Phil was instrumental in identifying high-impact targets for our platform technology, and his work ultimately allowed us to establish the interest of and obtain a major funding commitment from our first strategic venture investor. 


Phil played several critical roles during early stages of our start up, including honing pitches, developing a 5-year financial model, and identifying targets of broad interest to major investors.  Phil's contributions categorically enabled us to land a multi-million-dollar seed investment."


Kevin Weeks, PhD

Company In Development

Information coming soon. 

bottom of page